Related Experiment Video

Updated: Mar 28, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

1.0K

Does CDKN2A loss predict palbociclib benefit?

J Gao1, R P Adams, S M Swain

  • 1National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.;

Current Oncology (Toronto, Ont.)
|December 31, 2015
PubMed

Insights

Palbociclib, a cyclin-dependent kinases 4 and 6 inhibitor, shows promise for advanced breast cancer. A patient with CDKN2A loss experienced a clinical response to this targeted therapy.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Palbociclib is approved for hormone receptor-positive, HER2-negative advanced breast cancer.
  • Patients with CDKN2A loss were not specifically studied in initial trials.

Purpose of the Study:

  • To report a case of a patient with metastatic breast cancer and CDKN2A loss who responded to palbociclib.

Main Methods:

  • Case report of a patient with metastatic estrogen receptor-positive, HER2-negative breast cancer.
  • Treatment with palbociclib, a CDK4/6 inhibitor.

Main Results:

  • The patient with CDKN2A loss experienced a clinical response to palbociclib.

Conclusions:

  • Palbociclib may be effective in patients with advanced hormone receptor-positive, HER2-negative breast cancer even with CDKN2A loss.
  • Further investigation into CDK4/6 inhibitors in this specific patient population is warranted.
Keywords:
Medical oncologybreast cancer

More Related Videos

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

7.3K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
823
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.8K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
6.3K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

2.0K